IJR News — today's news from every side

IJR News — today's news from every side

openserveblockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

News

Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

Experimental pancreatic cancer drug now available in Nebraska — Jul 23, 2026Daraxonrasib, an investigational KRAS-targeting drug, has shown the potential to more than double survival in stage IV pancreatic cancer compared with chemotherapy and is being offered through expanded access programs at Nebraska Medicine, with Ben Sasse publicly discussing his positive response. The FDA has accepted an NDA for daraxonrasib based on phase 3 trial results showing significant improvements in overall survival, progression-free survival, and response rate, signaling a possible breakthrough though not yet FDA approved.